GlassScriptPhysician profile
Carol J Langdoc
NPI 1144242777
$2,873.35
in general payments reported to CMS, 2019-2025
21 companies · $933 in 2025
The $933 reported for 2025 was more than what 78% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $85.52 · 2021: $162 · 2022: $497 · 2023: $464 · 2024: $471 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $702.20 | 2021-2025 | Nucala |
| Stryker Corporation | $639.37 | 2019-2025 | Na, Core, Sonopet Iq |
| Genzyme Corporation | $390.19 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $216.76 | 2021-2025 | Dupixent |
| Medtronic, INC. | $202.60 | 2022-2025 | Propel, Pteye Parathyroid Detection System |
| Aerin Medical INC. | $182.54 | 2019-2025 | |
| Optinose US, INC. | $91.75 | 2019-2022 | |
| Medtronic USA, INC. | $52.85 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $48.90 | 2024-2025 | Unithroid |
| Acclarent, INC | $42.36 | 2022-2023 | Trudi Nav Cable |
| Ethicon US, LLC | $41.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $40.83 | 2025 | Tezspire |
| Kaleo, INC. | $33.42 | 2022 | |
| Lucid Diagnostics INC. | $33.37 | 2022-2023 | |
| Neurent Medical Limited | $28.88 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cochlear Americas | $27.64 | 2024 | Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha |
| Novartis Pharmaceuticals Corporation | $23.60 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $22.58 | 2025 | Neffy |
| Intersect Ent, INC. | $21.89 | 2019 | |
| Ascendis Pharma Endocrinology INC | $17.02 | 2025 | Yorvipath |
| Integra Lifesciences Corporation | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Langdoc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.